Table 1.
Summary of the drug use in study intervals.
| Parameters | Basal (n = 21) | MTH (n = 20) | NT (n = 19) |
|---|---|---|---|
| UFH (ptn) | 4 (19%) | 0 (0%) | 0 (0%) |
| LMWH(ptn) | 1 (5%) | 2 (10%) | 1 (5%) |
| ASA(ptn) | 8 (38%) | 20 (100%)* | 17 (90%)^ |
| P2Y12 (ptn) | 2 (10%) | 20 (100%)* | 19 (100%)^ |
| Clopidogrel (ptn) | 2 (10%) | 0 (0%) | 0 (0%) |
| Ticagrelor (ptn) | 0 (0%) | 20 (100%) | 19 (100%)^ |
*
p < 0.05 (MTH vs. Basal);
^
p < 0.05 (NT vs. Basal)
ASA — acetylsalicylic acid; LMVH — low molecular weight heparin; MTH — mild therapeutic hypothermia; NT — normothermia; P2Y12 — inhibitor P2Y12; UFH — unfractionated heparin; ptn — patients
(1) All patients in hypothermia received dual antiplatelet therapy (ASAMTH = 100% vs. ASABasal = 38%; p < 0.05) and (P2Y12MTH = 100% vs. P2Y12Basal = 10%; p < 0.05).
(2) In 2 normothermic patients, ASA was discontinued due to bleeding from the respiratory tract and suspicion of central nervous system bleeding.
(3) All patients in normothermia received P2Y12.